Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:ELEV NASDAQ:EXOZ NYSE:JATT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.12+1.2%$1.81$1.27▼$4.75$83.41M1.71222,044 shs101 shsELEVElevation Oncology$0.37$0.37$0.27▼$0.40$21.62M1.481.34 million shsN/AEXOZeXoZymes$10.00$8.92$7.08▼$18.40$84.79M2.855,459 shs721 shsJATTJATT Acquisition$10.50$7.32$9.99▼$11.31$81.90MN/A14,578 shs8,717 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-5.00%-5.86%+40.27%-6.28%-37.63%ELEVElevation Oncology0.00%0.00%0.00%0.00%+9.77%EXOZeXoZymes+1.01%+0.20%-0.29%-4.85%-9.09%JATTJATT Acquisition-0.48%-3.27%+74.13%+85.19%+760.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.12+1.2%$1.81$1.27▼$4.75$83.41M1.71222,044 shs101 shsELEVElevation Oncology$0.37$0.37$0.27▼$0.40$21.62M1.481.34 million shsN/AEXOZeXoZymes$10.00$8.92$7.08▼$18.40$84.79M2.855,459 shs721 shsJATTJATT Acquisition$10.50$7.32$9.99▼$11.31$81.90MN/A14,578 shs8,717 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-5.00%-5.86%+40.27%-6.28%-37.63%ELEVElevation Oncology0.00%0.00%0.00%0.00%+9.77%EXOZeXoZymes+1.01%+0.20%-0.29%-4.85%-9.09%JATTJATT Acquisition-0.48%-3.27%+74.13%+85.19%+760.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.25Hold$2.7530.02% UpsideELEVElevation Oncology 2.00HoldN/AN/AEXOZeXoZymes 1.00SellN/AN/AJATTJATT Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ELEV, EXOZ, JATT, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.003/12/2026BTMDbiote National Bank FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$2.503/12/2026BTMDbiote TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.503/12/2026BTMDbiote B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$192.22M0.44$0.56 per share3.79($1.40) per share-1.51ELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/AEXOZeXoZymesN/AN/AN/AN/A$0.40 per shareN/AJATTJATT AcquisitionN/AN/A$0.39 per share27.08($0.53) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$27.05M$0.754.7911.13N/A8.29%-24.04%14.46%N/AELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%N/AEXOZeXoZymes-$9.16M-$1.08N/AN/AN/AN/A-147.18%-104.98%N/AJATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/ALatest ELEV, EXOZ, JATT, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 million3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/A3/11/2026Q4 2025BTMDbiote$0.05$0.06+$0.01$0.06$45.79 million$46.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.220.79ELEVElevation Oncology0.6719.4019.40EXOZeXoZymes0.022.512.51JATTJATT AcquisitionN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%ELEVElevation Oncology83.70%EXOZeXoZymesN/AJATTJATT Acquisition47.97%Insider OwnershipCompanyInsider OwnershipBTMDbiote32.40%ELEVElevation Oncology8.10%EXOZeXoZymes72.41%JATTJATT Acquisition20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19439.55 million26.74 millionNot OptionableELEVElevation Oncology4059.22 million54.43 millionOptionableEXOZeXoZymes298.48 million2.34 millionN/AJATTJATT Acquisition37.80 million13.80 millionNot OptionableELEV, EXOZ, JATT, and BTMD HeadlinesRecent News About These CompaniesJATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public OfferingApril 20, 2026 | globenewswire.comJATT II Acquisition Corp.April 19, 2026 | edition.cnn.comAmanat Acquisition Files for $75M IPOApril 17, 2026 | marketwatch.comJATT II Acquisition Corp prices $60 million IPO at $10 per shareApril 17, 2026 | investing.comJATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public OfferingApril 16, 2026 | globenewswire.comJatt II Acquisition Files for IPOMarch 13, 2026 | marketwatch.comCautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive RisksDecember 25, 2024 | markets.businessinsider.comZura Bio (ZURA) Receives a Buy from Piper SandlerDecember 12, 2024 | markets.businessinsider.comCautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial UncertaintyNovember 11, 2024 | markets.businessinsider.comThe Legend of Maula Jatt Review: Fawad Khan’s GoT-Coded War Epic Is Derivative, RIdden With ClichesOctober 4, 2024 | moneycontrol.comRelease of Fawad Khan’s Pakistani blockbuster ‘The Legend of Maula Jatt’ halted in IndiaOctober 4, 2024 | thehindu.comPakistani hit The Legend of Maula Jatt, starring Fawad Khan, Mahira Khan, not to release in India, confirms distributorOctober 4, 2024 | hindustantimes.comHIndia puts blockbuster Pakistani film on holdOctober 4, 2024 | bbc.co.uk"What is need to release Pakistani film in India?" Shiv Sena (UBT) opposes release of 'The Legend of Maula Jatt'September 22, 2024 | malaysiasun.comMShiv Sena (UBT) leader Anand Dubey opposes release of Pakistani film 'The Legend of Maula Jatt' in IndiaSeptember 22, 2024 | malaysiasun.comM‘Jatt & Juliet 3’ OTT release: When and where to watch the Diljit Dosanjh and Neeru Bajwa starrer rom-comAugust 27, 2024 | timesofindia.indiatimes.comBahdarpur Jatt Pin CodeApril 9, 2024 | indiatvnews.comINishikant Dubey, wife booked in med college acquisition caseMarch 31, 2024 | timesofindia.indiatimes.comSen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. SteelDecember 22, 2023 | pennlive.comPMicrosoft poised to close massive Activision Blizzard acquisition next weekOctober 9, 2023 | vg247.comVNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Insurance Stocks That Can Act as a New Inflation Hedge By Chris Markoch | April 16, 2026$39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent InflationBy Chris Markoch | April 19, 2026Chevron's Pullback May Be a Buying Opportunity—Even If the War EndsBy Sam Quirke | April 26, 20263 Agriculture Stocks to Buy as Food Inflation Stays Elevated in 2026By Chris Markoch | April 20, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026ELEV, EXOZ, JATT, and BTMD Company Descriptionsbiote NASDAQ:BTMD$2.12 +0.03 (+1.20%) As of 09:37 AM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Elevation Oncology NASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.eXoZymes NASDAQ:EXOZ$10.00 0.00 (0.00%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.JATT Acquisition NYSE:JATT$10.50 0.00 (0.00%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
